INT230018

Context Info Confidence 0.21 First Reported 2008 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 2 Total Number 2 Disease Relevance 0.86 Pain Relevance 0.74

transport (Slc17a5) cytoplasmic membrane-bounded vesicle (Slc17a5) plasma membrane (Slc17a5) transmembrane transport (Slc17a5) lysosome (Slc17a5)

Slc17a5 (Mus musculus)

Pain Link Frequency Relevance Heat diclofenac 3 99.66 cINOD 24 97.70 Paracetamol 107 96.56 Osteoarthritis 46 55.04 Pain 20 53.60 COX-2 inhibitor 8 47.60 Acute pain 2 43.68 Inflammation 25 32.56 Arthritis 21 5.00 cva 13 5.00

Disease Link Frequency Relevance Heat Congenital Anomalies 3 99.96 Toxicity 43 99.00 Hepatotoxicity 10 83.92 Drug Induced Neurotoxicity 4 76.48 Osteoarthritis 46 55.04 Pain 23 53.60 INFLAMMATION 27 32.56 Cancer 9 5.16 Arthritis 20 5.00 Disease 18 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

This suggests that ALT, AST and BUN may be valid early indicators for monitoring emerging toxicity in patients undergoing treatment with sunitinib and paracetamol.

AST Binding (indicators) of associated with toxicity and paracetamol

1) Confidence 0.21 Published 2010 Journal BMC Pharmacol Section Body Doc Link PMC2965131 Disease Relevance 0.60 Pain Relevance 0.40

However, the incidence rate for lumiracoxib 100 mg o.d. is similar to that reported in the prescribing information for many NSAIDs (1% or less), such as naproxen and ibuprofen [33,34], and less than that observed with diclofenac, which has been associated with ALT and AST abnormalities in 3.2% and 1.8% of patients, respectively [35].

AST Binding (associated) of associated with congenital anomalies, cinod and diclofenac

2) Confidence 0.06 Published 2008 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2322990 Disease Relevance 0.26 Pain Relevance 0.34

General Comments

This test has worked.